Sign in to view content

An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD

Marco A. Zarbin, MD, PhD

Video
Published 2023

Related

Intravitreal Aflibercept 8 mg in Patients With Polypoidal Choroidal Vasculopathy Phase 3 PULSAR Trial Subgroup Analysis
David T.W. Wong, MD, FRCS(C), FASRS
Annual Meeting Talks
2023
Baseline Characteristics of Patients Maintaining q12 and q16 Dosing With Aflibercept 8 mg vs Patients With Shortened Treatment Intervals Phase 3 PULSAR Post Hoc Analysis
David R. Chow, MD, FRCS(C)
Annual Meeting Talks
2023
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more